FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (XII), where:
represents
ring B is selected from the group consisting of phenyl and pyridyl; R16 is -C(=O)R11; R3 represents hydrogen; R4 represents -ORb; L represents bond; ring A is a 5-membered heteroaryl containing three nitrogen atoms, where ring A may be optionally replaced by one RA; RA is selected from the group consisting of C1-C6alkyl and C1-C6 deuteroalkyl; R5 is selected from the group consisting of -NR9R10, -NR8S(=O)R7, NR8C (=O) NR9R10, NR8C(=O)R7 and 4–5-membered heterocycloalkyl containing two nitrogen atoms; where heterocycloalkyl is substituted with two substituents, each of which is independently selected from the group consisting of oxo and C1-C6alkyl; R7 is selected from the group consisting of C1-C6alkyl and C3-cycloalkyl; R8 represents hydrogen; R9 and R10 are independently selected from the group consisting of hydrogen, C1-C6alkyl and 5–6-membered heteroaryl containing one or two nitrogen atoms; wherein the heteroaryl is optionally substituted with one or two substituents, each independently selected from the group consisting of oxo, halogen, -CN, C1-C6alkyl and morpholinyl; or R9 and R10 together with the nitrogen atom to which they are attached form a 4-membered heterocycloalkyl containing one nitrogen atom optionally substituted by two substituents selected from C1-C6alkyl; R11 is selected from the group consisting of C1-C6alkyl, C1-C6deuteroalkyl and C3-cycloalkyl; wherein each alkyl and cycloalkyl is optionally substituted with one R11a; R11a is selected from halogen; Rb is selected from C1-C6alkyl. The invention also relates to specific compounds and a pharmaceutical composition based on these compounds and the compound of formula (XII).
EFFECT: obtaining new compounds and a pharmaceutical composition based on them which can be used in medicine in the treatment and prevention of cancer.
12 cl, 10 tbl, 203 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
| JAK-INHIBITING TRIAZOLOPYRIDINE COMPOUNDS AND METHODS | 2009 |
|
RU2560153C2 |
| PYRROLOPYRIMIDINE COMPOUNDS AND APPLICATION THEREOF | 2011 |
|
RU2563644C2 |
| CONDENSED HETEROARYLS AND THEIR APPLICATION | 2011 |
|
RU2552114C2 |
| BICYCLIC COMPOUNDS AS PD1/PD-L1 INTERACTION/ACTIVATION INHIBITORS | 2019 |
|
RU2777980C2 |
| COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2019 |
|
RU2795108C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2015 |
|
RU2707749C2 |
| CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | 2016 |
|
RU2732405C2 |
| CONDENSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2700004C1 |
